STOCK TITAN
  1. Home
  2. News
  3. IMCR

Immunocore Holdings plc - IMCR STOCK NEWS

Welcome to our dedicated news page for Immunocore Holdings plc (Ticker: IMCR), a resource for investors and traders seeking the latest updates and insights on Immunocore Holdings plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immunocore Holdings plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immunocore Holdings plc's position in the market.

News
Immunocore to present at upcoming investor conferences
Rhea-AI Summary
Immunocore Holdings plc (IMCR) announced its participation in upcoming investor conferences to discuss its transformative immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases. The presentations will be webcast live and accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
conferences
-
News
Immunocore presented two posters at CROI 2024
Rhea-AI Summary
Immunocore presents two posters at CROI 2024 highlighting the significance of TCR biology in developing new HIV treatments. The company showcased preclinical data at the Conference on Retroviruses and Opportunistic Infections, emphasizing the potential for transformative immunomodulating medicines in cancer, infectious diseases, and autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
none
-
News
Immunocore to present at upcoming investor conferences
Rhea-AI Summary
Immunocore Holdings plc (IMCR) to present at several investor conferences in March 2024, showcasing their transformative immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
conferences
News
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
Rhea-AI Summary
Immunocore reports strong financial results for Q4 and full year 2023, with net revenues of $67.6 million in Q4 and $238.7 million in 2023 from KIMMTRAK sales. The company is expanding commercial access to KIMMTRAK globally and initiating registrational trials in melanoma. Clinical trial collaborations with Bristol Myers Squibb and upcoming data readouts for various programs show promising growth prospects. Immunocore's financials indicate increased net sales and R&D expenses, with a net loss of $55.3 million for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
earnings
-
News
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
Rhea-AI Summary
Immunocore collaborates with Bristol Myers Squibb to evaluate IMC-F106C in combination with nivolumab for advanced melanoma treatment in a Phase 3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
clinical trial
-
News
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
Rhea-AI Summary
Immunocore Holdings plc (Nasdaq: IMCR) will report full year 2023 financial results on February 28, 2024. The Company aims to improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases through transformative immunomodulating medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
conferences earnings
News
DELFI Diagnostics Announces Availability of New Fragmentome-Based Cancer Treatment Monitoring Assay
Rhea-AI Summary
DELFI Diagnostics, Inc. has announced the availability of the DELFI-Tumor Fraction (DELFI-TF) assay, a highly sensitive and inexpensive means of noninvasive measurement of tumor burden and assessing treatment response and resistance in patients with advanced cancer. The company has also entered a new research collaboration with Immunocore Holdings plc (Nasdaq: IMCR) to explore the use of the DELFI-TF cancer monitoring assay as an early predictor of benefit from treatment with ImmTAC-based therapies. The assay delivers a genome-wide measure of the proportion of cfDNA derived from a tumor and has numerous advantages, including low cost and minimal plasma requirement. The assay is also being evaluated by additional parties across the pharmaceutical industry for its potential application in advancing other healthcare discoveries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.04%
Tags
none
-
News
Immunocore Prices Upsized Convertible Senior Notes Offering
Rhea-AI Summary
Immunocore Holdings plc (IMCR) announced the pricing of $350.0 million aggregate principal amount of 2.50% convertible senior notes due 2030 in a private offering to qualified institutional buyers. The offering was upsized from the previously announced offering of $300.0 million aggregate principal amount of convertible senior notes. The notes will mature on February 1, 2030, unless earlier converted, redeemed, or repurchased. Immunocore estimates that the net proceeds from the offering will be approximately $338.4 million (or approximately $389.3 million if the initial purchasers exercise their option to purchase additional notes in full), after deducting the initial purchasers’ discounts and commissions and estimated offering expenses payable by Immunocore. Immunocore intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to accelerate its clinical pipeline and for ongoing commercial expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.87%
Tags
none
-
News
Immunocore Announces Proposed Convertible Senior Notes Offering
Rhea-AI Summary
Immunocore Holdings plc (Nasdaq: IMCR) announced its intention to offer $300.0 million aggregate principal amount of convertible senior notes due 2030 in a private offering to qualified institutional buyers. The notes will be senior, unsecured obligations and will accrue interest payable semi-annually in arrears. Immunocore plans to use the net proceeds to accelerate its clinical pipeline and for ongoing commercial expansion, as well as to repay loans outstanding under its loan agreement with investment funds managed by Pharmakon Advisors, LP.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.19%
Tags
none
News
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
Rhea-AI Summary
Immunocore Holdings plc (Nasdaq: IMCR) announces strategic priorities and pipeline expansion, including KIMMTRAK global commercial access, two registrational trials, multiple clinical readouts, and new autoimmune disease candidates. Preliminary unaudited cash and cash equivalents are approximately $443 million USD as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
none
Stock IMCR logo
Immunocore Holdings plc

Nasdaq:IMCR

IMCR Rankings

#1955 Ranked by Market Cap
#3608 Ranked by Stock Gains
N/A Ranked by Dividends

IMCR Stock Data

2.82B
32.22M
4.45%
82.24%
9.26%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United Kingdom
Abingdon

About IMCR

immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of the body’s own immune system to find and kill diseased cells. immunocore has established a robust technology platform which combines monoclonal t cell receptor (mtcr) targeting technology with an effector technology, anti-cd3 scfv, that catalyses the killing of the targeted diseased cells by the host’s own non-specific cytotoxic t cells. immunocore is developing a portfolio of products from the platform, called immtacs, for the treatment of cancer, chronic infectious disease and diabetes.